Georgiamune Pitch Deck: All 20 Slides + Teardown

See all 20 slides of the Georgiamune pitch deck — a 2023 Series A deck — with a slide-by-slide teardown of what the deck does well and where it falls short.

Georgiamune’s Series A deck is a clinical-heavy presentation that successfully bridges the gap between complex immunology and market opportunity. By focusing on Regulatory T cells (Tregs), the company addresses the >85% failure rate of current checkpoint inhibitors in cancer patients, as noted on slide 9. The deck stands out for its 'Pipeline First' approach, showcasing 11 distinct programs ranging from target identification to IND-enabling stages on slide 5. With a leadership roster featuring former executives from Pfizer, BMS, and Verily, the deck leverages institutional credibility to just…

Key takeaways

The Homeostasis Narrative: Balancing Cancer and Autoimmunity

Georgiamune’s pitch deck begins not with a product, but with a biological philosophy. Slide 3, titled 'Loss of immune system homeostasis can lead to autoimmune diseases and cancer,' sets the stage for a platform-based investment. By visualizing the immune system as a scale, the company positions itself to capture two massive, distinct markets using the same underlying expertise in T-cell reprogramming. This slide is a masterclass in simplifying complex immunology for a generalist VC audience while maintaining scientific rigor.

Slide 1-4: The Vision and Platform

The deck opens with a clean, high-contrast design. Slide 2 defines the mission: 'Developing first-in-class immunotherapies.' Slide 4 introduces the 'novel biologic platforms,' which include both antibodies and small molecules. This is a critical strategic move; by not being wedded to a single modality, Georgiamune suggests their platform is versatile enough to address various targets with the most effective chemical or biological tool available.

Slide 5: The Pipeline Powerhouse

Slide 5 is arguably the most important slide for a Series A biotech company. It lists 11 distinct projects. The 'Clinical Programs' section highlights three lead assets: GIM-122 (Dual-Functioning Antibody for Cancer), GIM-531 (Treg Inhibitor for Cancer), and GIM-407 (Treg Activator for Autoimmune). All three are marked as 'First-in-Class' and are shown in the 'IND Enabling' stage. This indicates that the $75M raise is likely intended to push these three assets into Phase 1 clinical trials. The depth of the 'Drug Candidates' and 'Development Programs' further down the slide suggests a long-term 'company-building' play rather than a single-asset 'project-finance' play.

Slide 6-7: Institutional Credibility

In biotech, the team is the collateral. Slide 7, 'Innovative and Experienced Leadership,' is a 'who's who' of the pharmaceutical industry. The inclusion of Samir N. Khleif, MD (110+ patents), Sean Parker (Parker Institute), and Mace Rothenberg (Former CMO, Pfizer) provides an immediate stamp of approval. For an investor, this roster reduces execution risk—these are individuals who have successfully navigated the FDA and large-scale clinical trials before.

Slide 8-10: The Oncology Problem Statement

Slide 9 provides the 'Why Now?' factor. It acknowledges that Checkpoint Inhibitors (ICIs) are a $33B market but highlights a glaring weakness: they are ineffective for many patients, with a failure rate of >85% . Slide 10 positions GIM-122 as the solution to this resistance. By framing the product as a necessary evolution of a proven $33B market, Georgiamune makes the commercial upside feel tangible and urgent.

Slide 11: The Verily Partnership

Slide 11 highlights a strategic partnership with Verily (an Alphabet company). This is a significant 'moat' slide. It explains how Georgiamune uses Verily’s molecular and real-world evidence solutions to discover biomarkers and drive efficient clinical development. In an era where clinical trial costs are skyrocketing, showing a tech-enabled path to efficiency is a strong selling point for Series A investors.

Slide 12-20: Technical Deep Dive into Tregs

The final third of the deck focuses on the specific mechanism of action (MoA) regarding Regulatory T cells (Tregs). Slide 16 is particularly effective, contrasting Georgiamune’s 'selective' approach with 'current Treg depleting agents' that cause off-target effects. It argues that existing therapies (targeting CTLA4, CCR8, or CCR4) eliminate favorable effector T cells, whereas Georgiamune’s targets are 'highly selective to Tregs and not other cell types' (Slide 15). Slide 17 quantifies the oncology opportunity by US prevalence, citing 1.3M Melanoma cases and 730K Lung Cancer cases, grounding the science in market reality.

What Georgiamune Does Well

1. The Dual-Market Strategy: By using the same T-cell expertise to target both cancer (inhibition) and autoimmune disease (activation), Georgiamune creates a 'hedge' for investors. If one therapeutic area faces regulatory hurdles, the other provides a path forward.

2. Visualizing the 'Gap': Slide 9’s use of the >85% failure rate for ICIs is a powerful way to frame the problem. It doesn't attack the current standard of care; it identifies the massive population the standard of care leaves behind.

3. Heavyweight Endorsements: The board and advisor slides are not just names; they are strategic assets. Having a former FDA Deputy Commissioner (Amy Abernethy) on the board is a clear signal that the company is prepared for the regulatory gauntlet.

What is Missing from the Deck

1. The 'Ask' and Use of Funds: There is no slide detailing how much capital is being raised or how it will be allocated across the 11 pipeline programs. While we know from external reports that they raised $75M, the deck itself is silent on the financial requirements.

2. Clinical Data: While the deck mentions 'groundbreaking scientific discoveries,' it lacks specific data plots (e.g., mouse model tumor shrinkage or T-cell activation assays) in this summary version. Investors in a $75M round would typically see a much larger technical appendix with raw data.

3. Intellectual Property Detail: Although the CEO’s 110+ patents are mentioned, a specific slide detailing the patent estate (filing dates, jurisdictions, and coverage for lead assets GIM-122/531/407) is absent.

Founder's Guide: What to Copy

1. The Pipeline Graphic: Copy the layout of Slide 5. It clearly distinguishes between 'Clinical Programs,' 'Drug Candidates,' and 'Development Programs,' giving the impression of a mature, multi-asset company even at the Series A stage.

2. The 'Homeostasis' Framework: If your technology can be applied to multiple industries or disease states, use a 'balance' or 'spectrum' visual like Slide 3 to show how one platform solves two different problems.

3. The Partnership Slide: If you have a partnership with a major player (like Verily), don't just put their logo on a 'Partners' slide. Dedicate a full slide (like Slide 11) to explaining exactly how that partnership accelerates your development or reduces your risk.

Frequently asked questions

What is the primary biological mechanism Georgiamune is targeting?
Georgiamune focuses on Regulatory T cells (Tregs). As shown on slides 12 through 20, the company develops selective inhibitors to deplete Tregs in cancer (allowing the immune system to attack tumors) and selective activators to boost Tregs in autoimmune diseases (suppressing overactive immune responses).
How does Georgiamune differentiate itself from existing checkpoint inhibitors?
Slide 9 notes that current checkpoint inhibitors (ICIs) fail to activate the antitumor immune response in over 85% of patients. Georgiamune’s lead candidate, GIM-122, is presented as a dual-functioning antibody designed to overcome these specific resistance mechanisms.
Who are the key people behind Georgiamune?
The team is led by Founder/CEO Samir N. Khleif, MD, who holds over 110 patents. The board and advisors include high-profile figures like Sean Parker (Parker Institute), Mace Rothenberg (former CMO of Pfizer), and Amy Abernethy (former Deputy Commissioner of the FDA).
What is the status of their drug pipeline?
According to slide 5, Georgiamune has three lead clinical programs. GIM-122 and GIM-531 are in the IND-enabling phase for cancer, while GIM-407 is in the IND-enabling phase for autoimmune diseases. Several other candidates are in lead optimization or target identification.
Does the deck mention a specific fundraising goal?
No, the provided slides do not include an 'Ask' slide or a specific dollar amount. However, publisher-reported data from Business Insider confirms the company raised $75 million in a Series A round in 2023.
Cover slide of the Georgiamune pitch deck — Series A 2023
Georgiamune pitch deck, slide 1 (2023)

Georgiamune pitch deck: the facts

Company
Georgiamune
Year
2023
Stage
Series A
Slides
20
Sector
Biotech
Deck type
Series A Pitch Deck
Outcome
$75M Raised
Headquarters
North America

Georgiamune pitch deck PDF

The full Georgiamune deck is embedded on this page and can be read slide by slide in the browser — no download or account required. Each slide is covered in the breakdown above.

What the Georgiamune Inc. pitch deck was used for

This is Georgiamune’s 20‑slide **Series A pitch deck** used in 2023 to raise a **$75 million financing round** co-led by General Catalyst and the Parker Institute for Cancer Immunotherapy, with participation from Mubadala Capital, Alexandria Venture Investments, Catalio Capital Management, CJNV BioVenture, Verition Fund Management and others.[1][3][4][5][7][9][11][14][15] The company positions itself as a clinical-stage biotech developing first‑in‑class immunotherapies that re‑program T‑cell signaling to restore immune homeostasis in **cancer and autoimmune disease**, built around dual‑functioning antibodies and immune‑reprogramming small molecules, with platforms for functional T‑cell epitope discovery and T‑cell signaling plasticity.[1][2][5] The deck supports the IND‑stage launch of lead asset **GIM‑122**, a dual‑functioning antibody for checkpoint‑refractory or resistant solid tumors, and a broader preclinical pipeline spanning oncology and autoimmunity.[1][2][5][10] It also highlights a strategic partnership with Verily to deploy advanced molecular profiling and real‑world data for biomarker discovery and more efficient clinical development of GIM‑122 and other candidates.[2][

Business model: Clinical-stage biotechnology company developing first-in-class immunotherapies that re-program immune signaling pathways to treat oncology and autoimmune diseases.[1][2][5]

Round
Series A venture financing.[1][4][5][7][9][11][14][15]
Raised
$75 million.[1][3][4][5][7][9][11][14][15]
Lead investor
General Catalyst and Parker Institute for Cancer Immunotherapy (co-leads).
Investors
General Catalyst, Parker Institute for Cancer Immunotherapy (PICI), Mubadala Capital, Alexandria Venture Investments, Catalio Capital Management, CJNV BioVenture, Verition Fund Management, (Some databases also list BioVentures Investors / ARE among participants.)[9][11]
Headquarters
Gaithersburg, Maryland (U.S.).[5]
Industry
Biotechnology; oncology and autoimmune disease immunotherapies.[1][2][5]

Year: 2023.[1][4][5][7][9][11][14][15]

Total funding: $75 million in venture financing (Series A) as of August 2023.[1][3][4][5][7][9][11][14][15]

Use of funds as presented: To advance GIM-122 through clinical development and broader pipeline programs in oncology and autoimmune diseases, following FDA IND clearance and positioning Georgiamune as a new biotechnology company in these fields.[1][4][5][10][13]

What happened after the Georgiamune Inc. deck

Since using this deck to raise $75M in its August 2023 Series A, Georgiamune has obtained FDA IND clearance and initiated a phase 1/2 trial for lead asset GIM-122, formed a strategic biomarker and data partnership with Verily, and reported progress toward advancing additional oncology programs into clinical development.[1][2][4][5][10][11][13]

What the Georgiamune Inc. deck got right

What could have been stronger

How an investor would read this deck

What draws attention

Risks that stand out

Questions this deck invites

What founders can take from the Georgiamune Inc. deck

Georgiamune Inc. pitch deck: common questions

What does Georgiamune do?

Georgiamune is a privately held, clinical-stage biotechnology company based in Gaithersburg, Maryland that develops first-in-class immunotherapies by reprogramming immune signaling pathways to redirect the immune system against cancer and autoimmune diseases.[1][2][5] Its lead asset, GIM-122, is a dual-functioning monoclonal antibody in a phase 1/2 trial for checkpoint-refractory or resistant advanced solid tumors.[2]

How much did Georgiamune raise in its Series A and who invested?

Georgiamune raised a $75 million Series A round on August 9, 2023.[1][4][5][7][9][11][14][15] The financing was co-led by General Catalyst and the Parker Institute for Cancer Immunotherapy (PICI), with additional participation from Mubadala Capital, Alexandria Venture Investments, Catalio Capital Management, CJNV BioVenture, Verition Fund Management and related investors.[1][3][4][7][9][11][15]

What is special about Georgiamune’s pitch deck?

The deck under analysis is Georgiamune’s 20-slide Series A pitch deck used to secure the $75M financing round in 2023.[3] It presents the company’s immune-reprogramming platforms, pipeline (including GIM-122 and multiple oncology and autoimmune programs), intellectual property position, and strategic partnership with Verily, and was later featured by Business Insider.[3][11]

When did Georgiamune close its $75M Series A round?

According to Georgiamune’s own announcement and multiple investor databases, the $75M Series A was completed in August 2023, concurrent with FDA clearance of the IND for GIM-122.[1][4][5][9][11][14][15] Business Insider later reported on the deck and noted that the raise was co-led by General Catalyst and PICI.[3]

What is Georgiamune’s partnership with Verily about?

Georgiamune and Verily announced a strategic partnership in October 2023 to deploy Verily’s advanced molecular profiling and real-world evidence capabilities to support Georgiamune’s candidates.[2][6][8][10][13] The first application is immune mapping with Verily’s Immune Profiler for GIM-122, aiming to discover predictive and outcome biomarkers and make Georgiamune’s clinical development more efficient.[2][11][13]

Sources

Funding and outcome facts on this page were researched on 2026-08-30 from the pages below.

What the investor wrote

Investor-side writing matched to this company through dated, cited funding evidence.

General Catalyst

Related funding context

This investor wrote about a closely related funding event for this company, not verified as the same round.

January 1, 2023

  • Georgiamune is a clinical-stage biotechnology company developing potentially life-saving immunotherapies for cancer and autoimmune patients.
    “Georgiamune is a clinical stage biotechnology company founded by Dr. Samir N. Khleif to bring potentially life-saving immunotherapy to cancer and autoimmune patients.”
    Written at the time of the investment · Source
  • General Catalyst believes harnessing nature's machinery can generate cures for cancer patients resistant or unlikely to respond to existing immunotherapies.
    “At General Catalyst, we believe harnessing nature's machinery can help generate potentially life-saving cures for cancer patients that have become resistant to immunotherapy or would be unlikely to respond to existing immunotherapy approaches.”
    Written at the time of the investment · Source
  • Founder Dr. Samir N. Khleif discovered novel disease-driving targets within immune cell pathways to propel first-in-class therapeutics.
    “Dr. Khleif's work has led to the discovery of novel, disease-driving targets within immune cell pathways, propelling the development of potentially first-in-class immune therapeutics for cancer and autoimmune diseases.”
    Written at the time of the investment · Source
  • Georgiamune's lead candidate GIM-122 is a first-in-class monoclonal dual-functioning antibody designed to overcome immunotherapy resistance in solid tumors.
    “We believe Georgiamune's lead candidate, GIM-122, is a first-in-class, monoclonal dual-functioning antibody with a highly differentiated mechanism of action, that has the potential to offer differentiated efficacy and overcome resistance to immunotherapy in patients with solid tu”
    Written at the time of the investment · Source

What the deck itself said

Georgiamune pitch deck slides

Georgiamune pitch deck slide 1 of 20
Georgiamune pitch deck — slide 1 of 20
Georgiamune pitch deck slide 2 of 20
Georgiamune pitch deck — slide 2 of 20
Georgiamune pitch deck slide 3 of 20
Georgiamune pitch deck — slide 3 of 20
Georgiamune pitch deck slide 4 of 20
Georgiamune pitch deck — slide 4 of 20
Georgiamune pitch deck slide 5 of 20
Georgiamune pitch deck — slide 5 of 20
Georgiamune pitch deck slide 6 of 20
Georgiamune pitch deck — slide 6 of 20

What each slide of the Georgiamune pitch deck says

Slide 2

Developing first-in-class immunotherapies We use novel science to re-program the immune system to restore homeostasis in cancer and autoimmune diseases Overview: » Two state of the art drug development biological platforms + Spearheading advancements in therapeutics through innovative dual-functioning monoclonal antibodies (DFA) and small molecules for immune reprogramming « Deep pipeline with first-in-class therapeutics for cancer and autoimmune disease * Robust intellectual property portfolio

Slide 3

Loss of immune system homeostasis can lead to autoimmune diseases and cancer Over activated Healthy Under-activated T-cell Individual T-cell ) —— — — — @@ — — 'v.: . o ' Riwumatold Ml Asthritis S Autoimmune Olbcsse Over-active Immune Response Under-active Inmune Response Cancer = The immune system is regulated by a complex interplay of stimulatory and inhibitory signals that ensure its proper functioning by preventing excessive activation and suppression In a state of balance (homeostasis), the immune system can effectively distinguish and eliminate foreign invaders and abnormal cells, such as cancer cells, while avoiding self-attack, which is the hallmark of autoimmune diseases

Slide 4

Georgiamune developed novel biologic platforms to re-program T cells I. Functional T cell Epitope Discovery Platform II. T cell Signaling Plasticity Discovery Platform Differentiator Differentiator Reverse engineer novel biologic Comparative analysis functional signaling observations pathways of immune cell subsets Identify target receptors with novel biologic functional epitopes lghaling pattyvays; ols e identofication Development of T cell reprogramming SM selective to the target pathway Develop T cell reprogramming Biologics/SM that target epitopes

Slide 5

Georgiamune Pipeline Our groundbreaking scientific discoveries have led to the development of pioneering therapeutics, including dual-functioning antibodies and immune-reprogramming small molecules CLINICAL Clinical Programs Dual-Functioning amss IoE R concer - 5 aummes Drug Candidates GIM-710 Undisclosed Y Autoimmune Development Programs GIM-0915 Undisclosed CQ Cancer emerwoass 4 GIM-0228 Undisclosed CQ Autoimmune GIM-0621 Undisclosed CQ Cancer GIM-1213-L Undisclosed Y Cancer GIM-1213s Other Targets Y 8D

Slide 9

Checkpoint Inhibitors have shifted the cancer therapy paradigm, +18 Different cancer types $33B Current global sales >85% Of treated cancer patients Since their first approval in 2011, immune checkpoint inhibitors (ICIs) have been widely approved for more than 18 different cancer types, covering nearly half of all cancer cases in the US Current global sales are estimated to be $33B, representing a multibillion-dollar opportunity ICls alleviate checkpoint-mediated immunosuppression, but fail to activate the antitumor immune response This failure is thought to drive ICI failure in >85% of treated cancer patients A novel approach is needed to overcome checkpoint resistance to increase response…

Slide 10

GIM-122 Dual Functioning GIM-122 Overcomes Limitations of Antibody with Novel MOA Checkpoint Inhibitors in Oncology GIM-122 Overcomes Suppressive Signal and Activates T Cells T cells inactivated by suppressive Checkpoint inhibitors GIM-122 blocks T cell inhibition tumor microenvironment block T cell suppression and activates T cells \/ e'/ CHECKPOINT / TUMOR CELL INHIBITOR GIM-122 UNINHIBITED T CELL INHIBITED T CELL UNINHIBITED T CELL ACTIVATED T CELL \ \ Y

Slide 11

Deploy Verily's advanced molecular and real-world evidence solutions discovery of predictive and outcome biomarkers. Biomarkers Strategic Partnership with Verily to Development Efficient Drive more efficient clinical development Clinical by incorporating clinical trial data and DeVelopmént longitudinal real-world data sources. verily

Slide text above is read directly from the Georgiamune deck PDF embedded on this page.

Related fundraising guides (24)

Decks from the same year (1)

Decks with a similar raise (1)

Browse companies alphabetically (1)

More pitch deck teardowns (16)

Recently published pitch deck teardowns (12)

Fundraising library · Pitch deck examples · Investor directory · Founder database